Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Finding Study of Intranasal Insulin in Healthy Participants
NCT05062785Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Generex Oral-lyn in cardiac arrest (SCA). Primary endpoint: Severe Hypoglycemia at 4 hours. Started Oct 2021; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT05062785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062785.